肿瘤全胰腺切除术后自体胰岛移植患者持续血糖监测和胰岛功能的长期评估:一项前瞻性研究的初步见解。

IF 6.3 2区 医学 Q1 ENDOCRINOLOGY & METABOLISM
Alessandro Csermely, Massimiliano Tuveri, Gabriella Lionetto, Martina Fontana, Giancarlo Mansueto, Anna Turazzini, Sara S Sheiban, Manuel Colombini, Federica Nocilla, Carlotta Marruganti, Raffaella Melzi, Rita Nano, Alessandro Mantovani, Riccardo C Bonadonna, Maddalena Trombetta, Lorenzo Piemonti, Roberto Salvia
{"title":"肿瘤全胰腺切除术后自体胰岛移植患者持续血糖监测和胰岛功能的长期评估:一项前瞻性研究的初步见解。","authors":"Alessandro Csermely, Massimiliano Tuveri, Gabriella Lionetto, Martina Fontana, Giancarlo Mansueto, Anna Turazzini, Sara S Sheiban, Manuel Colombini, Federica Nocilla, Carlotta Marruganti, Raffaella Melzi, Rita Nano, Alessandro Mantovani, Riccardo C Bonadonna, Maddalena Trombetta, Lorenzo Piemonti, Roberto Salvia","doi":"10.1177/15209156251380857","DOIUrl":null,"url":null,"abstract":"<p><p><b><i>Background and Aims:</i></b> Total pancreatectomy with islet autotransplantation (TPIAT) is a surgical option to mitigate the risk of anastomotic complications and preserve endogenous insulin secretion in patients undergoing pancreaticoduodenectomy. However, the utility of continuous glucose monitoring (CGM) in assessing islet graft performance remains poorly characterized. Thereby, the aim of this study was to investigate the relationship between CGM-derived glycemic metrics and islet function following TPIAT. <b><i>Materials and Methods:</i></b> Ten patients with pancreatic neoplasms (male/female 5/5, median age 60 [IQR 55-68] years) underwent TPIAT between September 2023 and March 2025 at the Verona University Hospital, receiving a median islet dose of 1912 IEQ/kg [IQR 1724-3074]. CGM data were collected at 3 (<i>n</i> = 10), 6 (<i>n</i> = 8), and 12 (<i>n</i> = 7) months post-transplantation. Islet metabolic function was assessed using Igls criteria and BETA-2 score. CGM metrics were compared across Igls-defined graft function categories and correlated with BETA-2 scores. <b><i>Results:</i></b> Of 25 total assessments, islet function was classified as optimal (<i>n</i> = 10), good (<i>n</i> = 6), marginal (<i>n</i> = 8), or failure (<i>n</i> = 1). Median BETA-2 score decreased significantly across these groups (19.4, 13.6, 5.3, 1.4, respectively; <i>P</i> < 0.001). Optimal function was associated with superior glycemic control (time in range, TIR: 97.0%; time in tight range, TITR: 86.5%; time above range, TAR: 1.5%) and lower glycemic variability (coefficient of variation, CV: 20.5%; glycemia risk index, GRI: 44.0), compared with good and marginal groups (all <i>P</i> < 0.01). These same CGM metrics were significantly correlated with both Igls classification and BETA-2 score (all <i>P</i> < 0.015). <b><i>Conclusions:</i></b> CGM parameters reflect islet graft performance following TPIAT and are strongly correlated with established markers of β-cell function. Metrics such as TIR, TITR, TAR, CV, and GRI may serve as practical and sensitive tools for post-transplant metabolic surveillance in endocrine clinical practice. [Figure: see text].</p>","PeriodicalId":11159,"journal":{"name":"Diabetes technology & therapeutics","volume":" ","pages":""},"PeriodicalIF":6.3000,"publicationDate":"2025-09-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"Continuous Glucose Monitoring and Long-Term Assessment of Islet Function in Autologous Islet Transplantation after Total Pancreatectomy for Neoplasm: Preliminary Insights from a Prospective Study.\",\"authors\":\"Alessandro Csermely, Massimiliano Tuveri, Gabriella Lionetto, Martina Fontana, Giancarlo Mansueto, Anna Turazzini, Sara S Sheiban, Manuel Colombini, Federica Nocilla, Carlotta Marruganti, Raffaella Melzi, Rita Nano, Alessandro Mantovani, Riccardo C Bonadonna, Maddalena Trombetta, Lorenzo Piemonti, Roberto Salvia\",\"doi\":\"10.1177/15209156251380857\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><p><b><i>Background and Aims:</i></b> Total pancreatectomy with islet autotransplantation (TPIAT) is a surgical option to mitigate the risk of anastomotic complications and preserve endogenous insulin secretion in patients undergoing pancreaticoduodenectomy. However, the utility of continuous glucose monitoring (CGM) in assessing islet graft performance remains poorly characterized. Thereby, the aim of this study was to investigate the relationship between CGM-derived glycemic metrics and islet function following TPIAT. <b><i>Materials and Methods:</i></b> Ten patients with pancreatic neoplasms (male/female 5/5, median age 60 [IQR 55-68] years) underwent TPIAT between September 2023 and March 2025 at the Verona University Hospital, receiving a median islet dose of 1912 IEQ/kg [IQR 1724-3074]. CGM data were collected at 3 (<i>n</i> = 10), 6 (<i>n</i> = 8), and 12 (<i>n</i> = 7) months post-transplantation. Islet metabolic function was assessed using Igls criteria and BETA-2 score. CGM metrics were compared across Igls-defined graft function categories and correlated with BETA-2 scores. <b><i>Results:</i></b> Of 25 total assessments, islet function was classified as optimal (<i>n</i> = 10), good (<i>n</i> = 6), marginal (<i>n</i> = 8), or failure (<i>n</i> = 1). Median BETA-2 score decreased significantly across these groups (19.4, 13.6, 5.3, 1.4, respectively; <i>P</i> < 0.001). Optimal function was associated with superior glycemic control (time in range, TIR: 97.0%; time in tight range, TITR: 86.5%; time above range, TAR: 1.5%) and lower glycemic variability (coefficient of variation, CV: 20.5%; glycemia risk index, GRI: 44.0), compared with good and marginal groups (all <i>P</i> < 0.01). These same CGM metrics were significantly correlated with both Igls classification and BETA-2 score (all <i>P</i> < 0.015). <b><i>Conclusions:</i></b> CGM parameters reflect islet graft performance following TPIAT and are strongly correlated with established markers of β-cell function. Metrics such as TIR, TITR, TAR, CV, and GRI may serve as practical and sensitive tools for post-transplant metabolic surveillance in endocrine clinical practice. [Figure: see text].</p>\",\"PeriodicalId\":11159,\"journal\":{\"name\":\"Diabetes technology & therapeutics\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":6.3000,\"publicationDate\":\"2025-09-29\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"Diabetes technology & therapeutics\",\"FirstCategoryId\":\"3\",\"ListUrlMain\":\"https://doi.org/10.1177/15209156251380857\",\"RegionNum\":2,\"RegionCategory\":\"医学\",\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"Q1\",\"JCRName\":\"ENDOCRINOLOGY & METABOLISM\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"Diabetes technology & therapeutics","FirstCategoryId":"3","ListUrlMain":"https://doi.org/10.1177/15209156251380857","RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

摘要

背景和目的:全胰切除术联合胰岛自体移植(TPIAT)是胰十二指肠切除术患者降低吻合口并发症风险和保持内源性胰岛素分泌的一种手术选择。然而,持续血糖监测(CGM)在评估胰岛移植物性能方面的应用仍然缺乏明确的特征。因此,本研究的目的是研究TPIAT后cgm衍生的血糖指标与胰岛功能之间的关系。材料与方法:10例胰腺肿瘤患者(男/女5/5,中位年龄60 [IQR 55-68]岁)于2023年9月至2025年3月在维罗纳大学医院接受TPIAT治疗,胰岛中位剂量为1912 IEQ/kg [IQR 1724-3074]。在移植后3个月(n = 10)、6个月(n = 8)和12个月(n = 7)收集CGM数据。采用Igls标准和β -2评分评估胰岛代谢功能。在igls定义的移植物功能类别中比较CGM指标,并与BETA-2评分相关。结果:在总共25项评估中,胰岛功能分为最佳(n = 10)、良好(n = 6)、边缘(n = 8)和失败(n = 1)。两组的中位β -2评分均显著降低(分别为19.4、13.6、5.3、1.4,P < 0.001)。与良好组和边缘组相比,功能最优组血糖控制较好(范围内时间,TIR: 97.0%;范围内时间,TITR: 86.5%;范围以上时间,TAR: 1.5%),血糖变异性较低(变异系数,CV: 20.5%;血糖危险指数,GRI: 44.0)(均P < 0.01)。这些CGM指标与Igls分类和β -2评分均显著相关(均P < 0.015)。结论:CGM参数反映了TPIAT后胰岛移植的表现,并与β细胞功能的既定标志物密切相关。在内分泌临床实践中,TIR、TITR、TAR、CV和GRI等指标可作为移植后代谢监测的实用而敏感的工具。[图:见正文]。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
Continuous Glucose Monitoring and Long-Term Assessment of Islet Function in Autologous Islet Transplantation after Total Pancreatectomy for Neoplasm: Preliminary Insights from a Prospective Study.

Background and Aims: Total pancreatectomy with islet autotransplantation (TPIAT) is a surgical option to mitigate the risk of anastomotic complications and preserve endogenous insulin secretion in patients undergoing pancreaticoduodenectomy. However, the utility of continuous glucose monitoring (CGM) in assessing islet graft performance remains poorly characterized. Thereby, the aim of this study was to investigate the relationship between CGM-derived glycemic metrics and islet function following TPIAT. Materials and Methods: Ten patients with pancreatic neoplasms (male/female 5/5, median age 60 [IQR 55-68] years) underwent TPIAT between September 2023 and March 2025 at the Verona University Hospital, receiving a median islet dose of 1912 IEQ/kg [IQR 1724-3074]. CGM data were collected at 3 (n = 10), 6 (n = 8), and 12 (n = 7) months post-transplantation. Islet metabolic function was assessed using Igls criteria and BETA-2 score. CGM metrics were compared across Igls-defined graft function categories and correlated with BETA-2 scores. Results: Of 25 total assessments, islet function was classified as optimal (n = 10), good (n = 6), marginal (n = 8), or failure (n = 1). Median BETA-2 score decreased significantly across these groups (19.4, 13.6, 5.3, 1.4, respectively; P < 0.001). Optimal function was associated with superior glycemic control (time in range, TIR: 97.0%; time in tight range, TITR: 86.5%; time above range, TAR: 1.5%) and lower glycemic variability (coefficient of variation, CV: 20.5%; glycemia risk index, GRI: 44.0), compared with good and marginal groups (all P < 0.01). These same CGM metrics were significantly correlated with both Igls classification and BETA-2 score (all P < 0.015). Conclusions: CGM parameters reflect islet graft performance following TPIAT and are strongly correlated with established markers of β-cell function. Metrics such as TIR, TITR, TAR, CV, and GRI may serve as practical and sensitive tools for post-transplant metabolic surveillance in endocrine clinical practice. [Figure: see text].

求助全文
通过发布文献求助,成功后即可免费获取论文全文。 去求助
来源期刊
Diabetes technology & therapeutics
Diabetes technology & therapeutics 医学-内分泌学与代谢
CiteScore
10.60
自引率
14.80%
发文量
145
审稿时长
3-8 weeks
期刊介绍: Diabetes Technology & Therapeutics is the only peer-reviewed journal providing healthcare professionals with information on new devices, drugs, drug delivery systems, and software for managing patients with diabetes. This leading international journal delivers practical information and comprehensive coverage of cutting-edge technologies and therapeutics in the field, and each issue highlights new pharmacological and device developments to optimize patient care.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:604180095
Book学术官方微信